4lly
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
+ | |||
==Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A== | ==Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A== | ||
<StructureSection load='4lly' size='340' side='right' caption='[[4lly]], [[Resolution|resolution]] 1.60Å' scene=''> | <StructureSection load='4lly' size='340' side='right' caption='[[4lly]], [[Resolution|resolution]] 1.60Å' scene=''> | ||
Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4llu|4llu]], [[4llq|4llq]], [[4llw|4llw]], [[4llm|4llm]], [[4lld|4lld]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4llu|4llu]], [[4llq|4llq]], [[4llw|4llw]], [[4llm|4llm]], [[4lld|4lld]]</td></tr> | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lly FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lly OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lly RCSB], [http://www.ebi.ac.uk/pdbsum/4lly PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lly FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lly OCA], [http://pdbe.org/4lly PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4lly RCSB], [http://www.ebi.ac.uk/pdbsum/4lly PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4lly ProSAT]</span></td></tr> |
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
Line 15: | Line 16: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
+ | <div class="pdbe-citations 4lly" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 19:21, 11 August 2016
Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A
|
Categories: Human | Atwell, S | Chamberlain, A K | Demarest, S J | Guntas, G | Hansen-Estruch, C | Ho, C | Huang, F | Kuhlman, B | Leaver-Fay, A | Lewis, S M | Pustilnik, A | Sereno, A | Smith, E M | Truhlar, S M | Wu, X | Fab | Immune system